Elizabeth C. Ailes

Elizabeth C. Ailes

Auto-generated profile, based on publicly available information

Elizabeth C. Ailes

Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention , Atlanta, GA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Pediatrics
Verified
Journal Article
Closed access
PDF file
EAElizabeth C. Ailes
Elizabeth C. Ailes
SGSuzanne M. Gilboa
Suzanne M. Gilboa
MHMargaret A. Honein
Margaret A. Honein
MOMatthew E. Oster
Matthew E. Oster
BACKGROUND AND OBJECTIVES: In 2011, the US Secretary of Health and Human Services recommended universal screening of newborns for critical congenital heart defects (CCHDs), yet few estimates of the number of infants with CCHDs likely to be detected through universal screening exist. Our objective was to estimate the number of infants with nonsyndromic CCHDs in the United States likely to be detected (true positives) and missed (false negatives) through universal newborn CCHD screening. METHODS: We developed a simulation model based on estimates of birth prevalence, prenatal diagnosis, late detection, and sensitivity of newborn CCHD screening through pulse oximetry to estimate the number of true-positive and false-negative nonsyndromic cases of the 7 primary and 5 secondary CCHD screening targets identified through screening. RESULTS: We estimated that 875 (95% uncertainty interval [UI]: 705–1060) US infants with nonsyndromic CCHDs, including 470 (95% UI: 360–585) infants with primary CCHD screening targets, will be detected annually through newborn CCHD screening. An additional 880 (UI: 700–1080) false-negative screenings, including 280 (95% UI: 195–385) among primary screening targets, are expected. We estimated that similar numbers of CCHDs would be detected under scenarios comparing “lower” (∼19%) and “higher” (∼41%) than current prenatal detection prevalences. CONCLUSIONS: A substantial number of nonsyndromic CCHD cases are likely to be detected through universal CCHD screening; however, an equal number of false-negative screenings, primarily among secondary targets of screening, are likely to occur. Future efforts should document the true impact of CCHD screening in practice.

24 April 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAElizabeth C Ailes
Elizabeth C Ailes
WZWeiming Zhu
Weiming Zhu
ECElizabeth A Clark
Elizabeth A Clark
YHYa-Lin A Huang
Ya-Lin A Huang
MLMargaret A Lampe
Margaret A Lampe
KHKaren W Hoover
Karen W Hoover
Pregnancy is a condition of broad interest across many medical and health services research domains, but one not easily identified in healthcare claims data. Our objective was to establish an algorithm to identify pregnant women and their pregnancies in claims data. We identified pregnancy-related diagnosis, procedure, and diagnosis-related group codes, accounting for the transition to International Statistical Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis and procedure codes, in health encounter reporting on 10/1/2015. We selected women in Merative MarketScan commercial databases aged 15–49 years with pregnancy-related claims, and their infants, during 2008–2019. Pregnancies, pregnancy outcomes, and gestational ages were assigned using the constellation of service dates, code types, pregnancy outcomes, and linkage to infant records. We describe pregnancy outcomes and gestational ages, as well as maternal age, census region, and health plan type. In a sensitivity analysis, we compared our algorithm-assigned date of last menstrual period (LMP) to fertility procedure-based LMP (date of procedure + 14 days) among women with embryo transfer or insemination procedures. Among 5,812,699 identified pregnancies, most (77.9%) were livebirths, followed by spontaneous abortions (16.2%); 3,274,353 (72.2%) livebirths could be linked to infants. Most pregnancies were among women 25–34 years (59.1%), living in the South (39.1%) and Midwest (22.4%), with large employer-sponsored insurance (52.0%). Outcome distributions were similar across ICD-9 and ICD-10 eras, with some variation in gestational age distribution observed. Sensitivity analyses supported our algorithm’s framework; algorithm- and fertility procedure-derived LMP estimates were within a week of each other (mean difference: -4 days [IQR: -13 to 6 days]; n = 107,870). We have developed an algorithm to identify pregnancies, their gestational age, and outcomes, across ICD-9 and ICD-10 eras using administrative data. This algorithm may be useful to reproductive health researchers investigating a broad range of pregnancy and infant outcomes.

17 December 2013 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
EAElizabeth C. Ailes
Elizabeth C. Ailes
SGSuzanne M. Gilboa
Suzanne M. Gilboa
TRTiffany Riehle‐Colarusso
Tiffany Riehle‐Colarusso
CJCandice Y. Johnson
Candice Y. Johnson
CHCharlotte A. Hobbs
Charlotte A. Hobbs
TSThe National Birth Defects Prevention Study
The National Birth Defects Prevention Study
Objectives: Congenital heart defects (CHDs) occur in nearly 1% of live births. We sought to assess factors associated with prenatal CHD diagnosis in the National Birth Defects Prevention Study (NBDPS).Methods: We analyzed data from mothers with CHD‐affected pregnancies from 1998 to 2005. Prenatal CHD diagnosis was defined as affirmative responses to questions about abnormal prenatal ultrasounds and fetal echocardiography obtained during a structured telephone interview.Results: Fifteen percent (1097/7299) of women with CHD‐affected pregnancies (excluding recognized syndromes and single‐gene disorders) reported receiving a prenatal CHD diagnosis. Prenatal CHD diagnosis was positively associated with advanced maternal age, family history of CHD, type 1 or type 2 diabetes, twin or higher‐order gestation, CHD complexity, and presence of extracardiac defects. Prenatal CHD diagnosis was inversely associated with maternal Hispanic race/ethnicity, prepregnancy overweight or obesity, and preexisting hypertension. Prenatal CHD diagnosis varied by time to NBDPS interview and NBDPS study site.Conclusions: Further work is warranted to identify reasons for the observed variability in maternal reports of prenatal CHD diagnosis and the extent to which differences in health literacy or health system factors such as access to specialized prenatal care and fetal echocardiography may account for such variability. © 2013 John Wiley & Sons, Ltd.

28 November 2016 in Birth Defects Research Part A: Clinical and Molecular Teratology
Verified
Journal Article
Closed access
PDF file
EAElizabeth C. Ailes
Elizabeth C. Ailes
SGSuzanne M. Gilboa
Suzanne M. Gilboa
SGSimerpal K. Gill
Simerpal K. Gill
CBCheryl S. Broussard
Cheryl S. Broussard
KCKrista S. Crider
Krista S. Crider
TSThe National Birth Defects Prevention Study
The National Birth Defects Prevention Study

12 January 2018 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
EAElizabeth C. Ailes
Elizabeth C. Ailes
ASApril D. Summers
April D. Summers
ETEmmy L. Tran
Emmy L. Tran
SGSuzanne M. Gilboa
Suzanne M. Gilboa
KAKathryn E. Arnold
Kathryn E. Arnold
JRJennita Reefhuis
Jennita Reefhuis
Nitrofurantoin and trimethoprim-sulfamethoxazole commonly prescribed to women with urinary tract infections during first trimester of pregnancy.

1 June 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MMMarcela Mercado
Marcela Mercado
EAElizabeth C. Ailes
Elizabeth C. Ailes
MDMarcela Daza
Marcela Daza
VTVan T. Tong
Van T. Tong
JOJohana Osorio
Johana Osorio
MOMartha L. Ospina
Martha L. Ospina